Cagrilintide
InvestigationalLong-acting amylin analog
Also known as: AM833, CagriSema (with semaglutide)
Investigational. Not FDA approved. Studied alone and combined with semaglutide (CagriSema), which is under regulatory review.
A real evidence base, with gaps
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 44 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven so far: in trials, cagrilintide plus semaglutide (CagriSema) produced some of the largest weight loss seen for a GLP-1-based therapy. NOT yet approved. Standalone benefit and long-term safety are still being established.
What it is
Mimics amylin, a hormone that promotes satiety, complementing GLP-1 mechanisms.
What the research says
CagriSema led to large average weight loss in trials, among the highest reported for GLP-1-based drugs. Under FDA review with potential 2026 approval.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Cagrilintide is the intervention being tested.
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
FDA recalls & enforcement
Cagrilintide has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Not approved: long-term safety still being established.
- GI side effects reported in trials.
- No verified consumer supply exists yet.
Doses reported in studies & protocols
Trial doses only. There is no approved dose. This is not a recommendation.
Purity reality
No legitimate consumer supply. Treat gray-market product as unverified.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.